This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Alvogen FDA Rejection Leads to Class Action
Regulatory securities class action

Alvogen FDA Rejection Leads to Class Action

Analysis based on 15 articles · First reported Jan 29, 2026 · Last updated Feb 07, 2026

Sentiment
-50
Attention
4
Articles
15
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The market is negatively impacted by the news of Alvogen's regulatory setback, leading to a significant drop in its stock price. This event also creates opportunities for legal firms like the Rosen Law Firm specializing in securities class actions.

Pharmaceuticals Legal Services
Event Summary

Alvogen, a publicly traded company, faced a significant setback when the United States===Food and Drug Administration (FDA) issued a complete response letter for its Biologics License Application (BLA) for AVT05. The FDA cited deficiencies identified during a pre-license inspection of Alvogen's Reykjavik manufacturing facility. This news caused Alvogen's stock price to fall by 34% on November 3, 2025, and an additional 4% on November 4, 2025. In response, the Rosen Law Firm is preparing a class action lawsuit on behalf of Alvogen shareholders, alleging that Alvogen may have issued materially misleading business information to the investing public.

Key Actions
95 United States===Food and Drug Administration issued a complete response letter for Biologics License Application Alvogen
90 Alvogen stock price fell 34% and nearly 4%
85 Rosen Law Firm preparing a class action lawsuit Alvogen
Entities Involved
stock
Alvogen
Alvogen's stock price fell significantly after the United States===Food and Drug Administration (FDA) issued a complete response letter for its Biologics License Application for AVT05. This event has led to a class action lawsuit against Alvogen for allegedly issuing misleading business information.
Importance 100 Sentiment -70
govactor
United States===Food and Drug Administration
The United States===Food and Drug Administration (FDA) issued a complete response letter for Alvogen's Biologics License Application for AVT05, citing deficiencies that need to be resolved. This action directly triggered the decline in Alvogen's stock price and the subsequent class action.
Importance 90 Sentiment 0
priv
Rosen Law Firm
The Rosen Law Firm is preparing a class action lawsuit on behalf of Alvogen shareholders seeking recovery of investor losses, positioning itself as a key legal representative in this event.
Importance 80 Sentiment 60
per
Philip Kim
Philip Kim, an attorney at the Rosen Law Firm, is listed as a contact for investors interested in joining the class action against Alvogen.
Importance 40 Sentiment 50
per
Lawrence Rosen
Lawrence Rosen, a founding partner of the Rosen Law Firm, is mentioned as a key figure in the firm's success in securities class actions.
Importance 40 Sentiment 50
exch
Nasdaq
Alvogen's securities are traded on Nasdaq, which is the exchange where the stock price decline was observed.
Importance 10 Sentiment 0
cnt
Iceland
Alvogen's Reykjavik manufacturing facility, located in Iceland, was subject to a pre-license inspection by the United States===Food and Drug Administration (FDA), which identified deficiencies.
Importance 10 Sentiment 0
Relationships
Philip Kim related ↔ Rosen Law Firm
Lawrence Rosen related ↔ Rosen Law Firm
Alvogen related ↔ United States===Food and Drug Administration
Alvogen related ↔ Rosen Law Firm
Rosen Law Firm related ↔ United States===Food and Drug Administration
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.